Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance
Table 2
Associations of genotypes with prostate cancer risk, aggressiveness, and survival.
Factors
Race
GC/GC
GC/AT
AT/AT
Dom1 OR (95% CI)2
value
Additive1 OR (95% CI)2
value
Case/control
White
750/357
417/202
65/27
1.00 (0.82–1.23)
0.995
1.02 (0.86–1.21)
0.82
Black
49/68
9/16
2/1
0.87 (0.37–2.04)
0.75
1.00 (0.49–2.07)
0.99
Recurrence Y/N
White
205/544
100/316
20/45
0.86 (0.66–1.12)
0.25
0.92 (0.74–1.15)
0.48
Black
14/35
3/6
0/2
0.97 (0.21–4.36)
0.97
0.76 (0.22–2.69)
0.68
Gleason 8–10/≤7
White
44/589
14/336
2/51
0.55 (0.31–0.99)
0.04
0.61 (0.37–1.02)
0.06
Black
2/43
1/8
0/2
2.16 (0.17–26.99)
0.55
1.36 (0.19–9.92)
0.76
Stage 3 & 4/1 & 2
White
129/615
70/342
11/53
0.97 (0.71–1.31)
0.83
0.98 (0.76–1.26)
0.85
Black
8/40
1/8
0/2
0.46 (0.05–4.63)
0.51
0.43 (0.06–3.07)
0.40
HR (95% CI)3
value
HR (95% CI)3
value
Overall death Death/alive
White
160/590
68/348
17/48
0.76 (0.57–1.00)
0.05
0.87 (0.68–1.10)
0.24
Black
5/44
1/8
0/2
—
—
—
—
Specific death Other/PCa/alive
White
88/72/590
40/28/338
11/6/47
0.84 (0.58–1.21)4
0.35
0.93 (0.67–1.28)4
0.64
0.69 (0.45–1.06)5
0.09
0.81 (0.55–1.20)5
0.29
Black
3/2/44
1/0/8
0/0/2
—
—
—
—
Dom: dominant (AT/AT + GC/AT versus GC/GC); add: log-additive (per AT/AT).
2OR: odds ratio; CI: confidence interval; logistic model adjusted for age.
3HR: hazard ratio; for overall death, Cox model; for specific death, competing risk regression; all models adjusted for age.
4Other death cases versus alive.
5PCa death versus alive.
